2-[(3S)-3-(1H-indol-3-ylmethyl)morpholin-4-yl]-7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one | 913717-02-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-[(3S)-3-(1H-indol-3-ylmethyl)morpholin-4-yl]-7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one
• 英文别名: 7,7-dimethyl-2-[(3S)-3-(1H-indol-3-ylmethyl)morpholin-4-yl]-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one；(S)-2-(3-((1H-indol-3-yl)methyl)morpholino)-7,7-dimethyl-5,6,7,8-tetrahydrothiazolo[5,4-c]azepin-4-one；2-[(3S)-3-(1H-indol-3-ylmethyl)morpholin-4-yl]-7,7-dimethyl-6,8-dihydro-5H-[1,3]thiazolo[5,4-c]azepin-4-one
• CAS: 913717-02-9
• 化学式: C₂₂H₂₆N₄O₂S
• 分子量: 410.54
• InChiKey: ZCCMLCRXWWFYEG-HNNXBMFYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  98.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-[(3S)-3-(1H-indol-3-ylmethyl)morpholin-4-yl]-7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one 在 三氯氧磷 、 sodium azide 作用下， 以 甲醇 为溶剂， 反应 17.5h， 以22%的产率得到9-[(3S)-3-(1H-indol-3-ylmethyl)morpholin-4-yl]-6,6-dimethyl-6,7-dihydro-5H-tetrazolo[1,5-a][1,3]thiazolo[5,4-c]azepine
  参考文献：
  名称：

  [EN] TRICYCLIC KINASE INHIBITORS
  [FR] INHIBITEURS TRICYCLIQUES DE KINASE

  摘要：

  一系列融合的三环噻唑和噻吩衍生物，其在噻唑或噻吩环的2位被一个可选择取代的吗啡啉-4-基团取代，是选择性PI3激酶酶抑制剂，在医学上具有益处，例如在治疗炎症性、自身免疫性、心血管、神经退行性、代谢性、肿瘤学、疼痛性或眼科疾病方面。

  公开号：

  WO2009071890A1
• 作为产物：
  描述：

  3-bromo-6,6-dimethyl-azepane-2,4-dione 、 (3S)-3-(1H-indol-3-ylmethyl)morpholine-4-carbothioamide 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 以96%的产率得到2-[(3S)-3-(1H-indol-3-ylmethyl)morpholin-4-yl]-7,7-dimethyl-5,6,7,8-tetrahydro-4H-[1,3]thiazolo[5,4-c]azepin-4-one
  参考文献：
  名称：

  4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase

  摘要：

  4-(1,3-Thiazol-2-yl)morpholine derivatives have been identified as potent and selective inhibitors of phosphoinositide 3-kinase. The SAR data of selected examples are presented and the in vivo pro. ling of compound 18 is shown to demonstrate the utility of this class of compounds in xenograft models of tumor growth. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.06.076

文献信息

• Fused Thiazole Derivatives as Kinase Inhibitors
  申请人：Alexander Rikki Peter

  公开号：US20080306060A1

  公开（公告）日：2008-12-11

  A series of 5,6-dihydro-1,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.

  一系列取代在2位位置具有可选取代的morpholin-4-yl基团的5,6-二氢-1,3-苯并噻唑-7(4H)-酮衍生物及其类似物，是选择性PD激酶酶抑制剂，在医学上具有益处，例如在治疗炎症、自身免疫、心血管、神经退行性、代谢、肿瘤、疼痛或眼科疾病方面。
• FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS
  申请人：UCB Pharma, S.A.

  公开号：EP1881827B1

  公开（公告）日：2011-09-28
• Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
  申请人：Katsikis Peter D.

  公开号：US20110135655A1

  公开（公告）日：2011-06-09

  The invention includes compositions and methods for regulating PI3K p110 delta as an anti-retroviral therapy. The invention includes inhibiting p110 delta, a component of PI3K p110 delta signaling pathway, or any combination thereof in a cell as an anti-retroviral therapeutic approach for treating a retroviral infection, for example HIV. The invention includes a method of modulating PI3K p110 delta in a cell infected with a retrovirus by contacting the cell with an effective amount of a composition comprising an inhibitor of PI3K p110 delta.
• Compositions and Methods for Preventing or Treating Influenza Virus Infection
  申请人：Katsikis Peter D.

  公开号：US20120184519A1

  公开（公告）日：2012-07-19

  The invention includes compositions and methods for regulating PI3K p110 delta as an anti-retroviral therapy. The invention includes inhibiting p110 delta, a component of PI3K p110 delta signaling pathway, or any combination thereof in a cell as an anti-retroviral therapeutic approach for treating a retroviral infection, for example HIV. The invention includes a method of modulating PI3K p110 delta in a cell infected with a retrovirus by contacting the cell with an effective amount of a composition comprising an inhibitor of PI3K p110 delta.
• Role of PI3K P110 Delta Signaling in Retroviral Infection and Replication
  申请人：Katsikis Peter D.

  公开号：US20130116267A1

  公开（公告）日：2013-05-09

  The invention includes compositions and methods for regulating PI3K p110 delta as an anti-retroviral therapy. The invention includes a method of inhibiting p110 delta, a component of PI3K p110 delta signaling pathway, or any combination thereof in a cell as an anti-retroviral therapeutic approach for treating a retroviral infection, for example HTV. The invention includes a method of modulating PI3K p110 delta in a cell infected with a retrovirus by contacting the cell with an effective amount of a composition comprising an inhibitor of PI3K P110 delta.